they have plenty of cash..10 Nov 2021 15:29
Ilian Iliev, CEO of NetScientific, commented: "The Q3 2021 results by PDS show continued progress by the company in its clinical trials programme, strengthened team, and an ability to identify and exploit further opportunities. With $69.7m of cash at the end of period, the company is well funded to execute its strategy and exploit opportunities. We remain supportive of the PDS management and look forward to the pipeline development milestones in 2022 and 2023."
NetScientific's interest in PDS amounts to c. 4.72 per cent.